The Motley Fool: For Forest Labs, Inc, Deals Are Coming Fast And Furiex

This is definitely a season of deals in the health care space, with Forest Labs (NYSE: FRX  ) choosing to add another asset to its GI business ahead of its anticipated merger with Actavis (NYSE: ACT  ) . Forest Labs is offering a significant premium for Furiex Pharmaceuticals (NASDAQ: FURX  ) and there are still FDA-related risks in play, but it seems like a reasonable offer for what could prove to be a highly synergistic asset.

Read the full article here:
For Forest Labs, Inc, Deals Are Coming Fast And Furiex

Investopedia: Elan Shareholders Bring Management To Heel

Financial writers often lament that shareholders are too passive with respect to exercising their rights to oppose management decisions that they disagree with and holding management to account. Well, that can't be said about Elan's (NYSE:ELN) shareholders. Shareholders handed a significant and embarrassing collection of rejections to management, a move that I would argue expresses a very wise lack of confidence in management. With this rejection of management's strategy, I would hope that Elan management sees reason and seeks out the best deal available to sell the company.

Please read more here:
http://www.investopedia.com/stock-analysis/061713/elan-shareholders-bring-management-heel-eln-thrx-biib.aspx